We use cookies to improve your website experience. To learn about our use of cookies and how you can manage your cookie settings, please see our Cookie Policy. By continuing to use the website, you consent to our use of cookies.
Pink Sheet is part of Pharma Intelligence UK Limited
This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.
This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183
Sanofi licenses US rights to Pozen's cardiovascular disease prevention candidates; rights returned
02 Dec 2014
Executive Summary
Pozen Inc. (develops aspirin-based therapies for out-licensing) has granted Sanofi US exclusive rights to sell its PA8140 and PA32540, two tablets that each contain enteric-coated aspirin and the proton pump inhibitor omeprazole for the prevention of secondary cardiovascular diseases including coronary artery disease.
Deal Industry
Biotechnology
Pharmaceuticals
Deal Status
Terminated
Deal Type
Alliance
R&D and Marketing (Licensing)
Already a Biomedtracker subscriber?You have access to the full deal record through your subscription
Want to become a subscriber?Subscribers get more deal details, updates, deal financials and deal products.Questions?